London South East: First Patient Enrolled in Phase II Study - BP-101
(Alliance News) - Ovoca Bio PLC on Friday said the Russian Ministry of Health has not granted marketing authorisation for BP-101 after identifying issues with chemistry, manufacturing and controls.
Bio-Path Holdings Inc (NASDAQ:BPTH) has initiated a clinical development program for BP 101 A, targeting obesity and related metabolic diseases, marking the first non-cancer application of their ...